Top

Published in:

Open Access 01-12-2013 | Review

HLA-dependent tumour development: a role for tumour associate macrophages?

Authors: Maddalena Marchesi, Emilia Andersson, Lisa Villabona, Barbara Seliger, Andreas Lundqvist, Rolf Kiessling, Giuseppe V Masucci

Published in: Journal of Translational Medicine | Issue 1/2013

Abstract

HLA abnormalities on tumour cells for immune escape have been widely described. In addition, cellular components of the tumour microenvironment, in particular myeloid derived suppressor cells (MDSC) and alternatively activated M2 tumour-associated macrophages (TAMs), are involved in tumour promotion, progression, angiogenesis and suppression of anti-tumour immunity. However, the role of HLA in these activities is poorly understood. This review details MHC class I characteristics and describes MHC class I receptors functions. This analysis established the basis for a reflection about the crosstalk among the tumour cells, the TAMs and the cells mediating an immune response.

The tumour cells and TAMs exploit MHC class I molecules to modulate the surrounding immune cells. HLA A, B, C and G molecules down-regulate the macrophage myeloid activation through the interaction with the inhibitory LILRB receptors. HLA A, B, C are able to engage inhibitory KIR receptors negatively regulating the Natural Killer and cytotoxic T lymphocytes function while HLA-G induces the secretion of pro-angiogenic cytokines and chemokine thanks to an activator KIR receptor expressed by a minority of peripheral NK cells. The open conformer of classical MHC-I is able to interact with LILRA receptors described as being associated to the Th2-type cytokine response, triggering a condition for the M2 like TAM polarization. In addition, HLA-E antigens on the surface of the TAMs bind the inhibitory receptor CD94/NKG2A expressed by a subset of NK cells and activated cytotoxic T lymphocytes protecting from the cytolysis.

Furthermore MHC class II expression by antigen presenting cells is finely regulated by factors provided with immunological capacities. Tumour-associated macrophages show an epigenetically controlled down-regulation of the MHC class II expression induced by the decoy receptor DcR3, a member of the TNFR, which further enhances the M2-like polarization. BAT3, a positive regulator of MHC class II expression in normal macrophages, seems to be secreted by TAMs, consequently lacking its intracellular function, it looks like acting as an immunosuppressive factor.

In conclusion HLA could cover a considerable role in tumour-development orchestrated by tumour-associated macrophages.

Available only for authorised users

Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 11: 889-896. 10.1038/ni.1937.PubMed

Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006, 107: 2112-2122. 10.1182/blood-2005-01-0428.PubMed

Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000, 164: 6166-6173.PubMed

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23: 549-555. 10.1016/S1471-4906(02)02302-5.PubMed

Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N: IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009, 183: 6469-6477. 10.4049/jimmunol.0901575.PubMed

Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016/j.ccr.2005.02.013.PubMed

Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-867. 10.1038/nature01322.PubMedCentralPubMed

Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196: 254-265. 10.1002/path.1027.PubMed

Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010, 22: 231-237. 10.1016/j.coi.2010.01.009.PubMed

10.

Sica A, Mantovani A: Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012, 122: 787-795. 10.1172/JCI59643.PubMedCentralPubMed

11.

Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In’t Veld P, De Baetselier P, Van Ginderachter JA: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70: 5728-5739. 10.1158/0008-5472.CAN-09-4672.PubMed

12.

Bak SP, Alonso A, Turk MJ, Berwin B: Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol. 2008, 46: 258-268. 10.1016/j.molimm.2008.08.266.PubMedCentralPubMed

13.

Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A: Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000, 164: 762-767.PubMed

14.

Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009, 86: 1065-1073. 10.1189/jlb.0609385.PubMed

15.

Chen J, Li G, Meng H, Fan Y, Song Y, Wang S, Zhu F, Guo C, Zhang L, Shi Y: Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother. 2012, 61: 101-108. 10.1007/s00262-011-1094-3.PubMed

16.

Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR: CD277 Is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. Oncotarget. 2010, 1: 329-338.PubMedCentralPubMed

17.

Seliger B: Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother. 2012, 61: 249-254. 10.1007/s00262-011-1153-9.PubMed

18.

Schaefer MR, Williams M, Kulpa DA, Blakely PK, Yaffee AQ, Collins KL: A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J Immunol. 2008, 180: 7804-7817.PubMedCentralPubMed

19.

McCutcheon JA, Gumperz J, Smith KD, Lutz CT, Parham P: Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA. J Exp Med. 1995, 181: 2085-2095. 10.1084/jem.181.6.2085.PubMed

20.

Neisig A, Melief CJ, Neefjes J: Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. J Immunol. 1998, 160: 171-179.PubMed

21.

Demaria S, Schwab R, Bushkin Y: The origin and fate of beta 2m-free MHC class I molecules induced on activated T cells. Cell Immunol. 1992, 142: 103-113. 10.1016/0008-8749(92)90272-Q.PubMed

22.

Martayan A, Fraioli R, Giorda E, Setini A, Ciccarelli G, Delfino L, Ferrara GB, Giacomini P: Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer. 1999, 80: 639-649. 10.1038/sj.bjc.6690405.PubMedCentralPubMed

23.

Schnabl E, Stockinger H, Majdic O, Gaugitsch H, Lindley IJ, Maurer D, Hajek-Rosenmayr A, Knapp W: Activated human T lymphocytes express MHC class I heavy chains not associated with beta 2-microglobulin. J Exp Med. 1990, 171: 1431-1442. 10.1084/jem.171.5.1431.PubMed

24.

Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL: Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A. 2002, 99: 16180-16185. 10.1073/pnas.212643199.PubMedCentralPubMed

25.

Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, Goldman-Wohl D, Yagel S, Horejsi V, Levy O: Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol. 2003, 171: 1343-1351.PubMed

26.

Zilberman S, Schenowitz C, Agaugue S, Benoit F, Riteau B, Rouzier R, Carosella ED, Rouas-Freiss N, Menier C: HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment. Eur J Immunol. 2012, 42: 1599-1608. 10.1002/eji.201141761.PubMed

27.

Cochran JR, Cameron TO, Stern LJ: The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity. 2000, 12: 241-250. 10.1016/S1074-7613(00)80177-6.PubMed

28.

Shiroishi M, Kohda D, Maenaka K: Preparation and crystallization of the disulfide-linked HLA-G dimer. Biochim Biophys Acta. 2006, 1764: 985-988. 10.1016/j.bbapap.2005.10.006.PubMed

29.

Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K: Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem. 2006, 281: 10439-10447. 10.1074/jbc.M512305200.PubMed

30.

Apps R, Gardner L, Sharkey AM, Holmes N, Moffett A: A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol. 2007, 37: 1924-1937. 10.1002/eji.200737089.PubMedCentralPubMed

31.

Howangyin KY, Loustau M, Wu J, Alegre E, Daouya M, Caumartin J, Sousa S, Horuzsko A, Carosella ED, Lemaoult J: Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell Mol Life Sci. 2012, 69: 4041-4049. 10.1007/s00018-012-1069-3.PubMedCentralPubMed

32.

Pangault C, Le Friec G, Caulet-Maugendre S, Lena H, Amiot L, Guilloux V, Onno M, Fauchet R: Lung macrophages and dendritic cells express HLA-G molecules in pulmonary diseases. Hum Immunol. 2002, 63: 83-90. 10.1016/S0198-8859(01)00373-1.PubMed

33.

Ibrahim EC, Aractingi S, Allory Y, Borrini F, Dupuy A, Duvillard P, Carosella ED, Avril MF, Paul P: Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer. 2004, 108: 243-250. 10.1002/ijc.11456.PubMed

34.

Lefebvre S, Antoine M, Uzan S, McMaster M, Dausset J, Carosella ED, Paul P: Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002, 196: 266-274. 10.1002/path.1039.PubMed

35.

Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V: Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007, 67: 6433-6441. 10.1158/0008-5472.CAN-06-4588.PubMed

36.

Kren L, Muckova K, Lzicarova E, Sova M, Vybihal V, Svoboda T, Fadrus P, Smrcka M, Slaby O, Lakomy R: Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: a role in innate immunity?. J Neuroimmunol. 2010, 220: 131-135. 10.1016/j.jneuroim.2010.01.014.PubMed

37.

Schutt P, Schutt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, Rebmann V: Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol. 2010, 71: 489-495. 10.1016/j.humimm.2010.02.015.PubMed

38.

Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U: Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001, 92: 369-376. 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U.PubMed

39.

Rebmann V, Regel J, Stolke D, Grosse-Wilde H: Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol. 2003, 13: 371-377. 10.1016/S1044-579X(03)00028-2.PubMed

40.

Pistoia V, Morandi F, Wang X, Ferrone S: Soluble HLA-G: Are they clinically relevant?. Semin Cancer Biol. 2007, 17: 469-479. 10.1016/j.semcancer.2007.07.004.PubMedCentralPubMed

41.

Mach P, Blecharz P, Basta P, Marianowski P, Skret-Magierlo J, Kojs Z, Grabiec M, Wicherek L: Differences in the soluble HLA-G blood serum concentration levels in patients with ovarian cancer and ovarian and deep endometriosis. Am J Reprod Immunol. 2010, 63: 387-395. 10.1111/j.1600-0897.2009.00806.x.PubMed

42.

Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, Coiteux V, Yakoub-Agha I, Dubucquoi S, Avet-Loiseau H: Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin Cancer Res. 2005, 11: 7297-7303. 10.1158/1078-0432.CCR-05-0456.PubMed

43.

Amiot L, Le Friec G, Sebti Y, Drenou B, Pangault C, Guilloux V, Leleu X, Bernard M, Facon T, Fauchet R: HLA-G and lymphoproliferative disorders. Semin Cancer Biol. 2003, 13: 379-385. 10.1016/S1044-579X(03)00029-4.PubMed

44.

Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E: Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011, 78: 120-128. 10.1111/j.1399-0039.2011.01716.x.PubMed

45.

Morandi F, Scaruffi P, Gallo F, Stigliani S, Moretti S, Bonassi S, Gambini C, Mazzocco K, Fardin P, Haupt R: Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins. PLoS One. 2012, 7: e29922-10.1371/journal.pone.0029922.PubMedCentralPubMed

46.

Braud VM, Allan DS, Wilson D, McMichael AJ: TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol. 1998, 8: 1-10.PubMed

47.

Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE: HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol. 1998, 160: 4951-4960.PubMed

48.

Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B: Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood. 2007, 109: 2806-2814.PubMed

49.

Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, Sperduti I, Lo Monaco E, Cosimelli M, Giacomini P: High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med. 2011, 9: 184-10.1186/1479-5876-9-184.PubMedCentralPubMed

50.

Silva TG, Crispim JC, Miranda FA, Hassumi MK, de Mello JM, Simoes RT, Souto F, Soares EG, Donadi EA, Soares CP: Expression of the nonclassical HLA-G and HLA-E molecules in laryngeal lesions as biomarkers of tumor invasiveness. Histol Histopathol. 2011, 26: 1487-1497.PubMed

51.

Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T: HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A. 2011, 108: 10656-10661. 10.1073/pnas.1100354108.PubMedCentralPubMed

52.

de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ: HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol. 2010, 185: 7452-7459. 10.4049/jimmunol.1002629.PubMed

53.

Levy EM, Bianchini M, Von Euw EM, Barrio MM, Bravo AI, Furman D, Domenichini E, Macagno C, Pinsky V, Zucchini C: Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. 2008, 32: 633-641.PubMed

54.

Derre L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N: Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol. 2006, 177: 3100-3107.PubMed

55.

Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M: HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol. 2005, 64: 523-528.PubMed

56.

Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Jimenez P, Geraghty DE, Garrido F: Analysis of HLA-E expression in human tumors. Immunogenetics. 2003, 54: 767-775.PubMed

57.

Palmisano GL, Contardi E, Morabito A, Gargaglione V, Ferrara GB, Pistillo MP: HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. Hum Immunol. 2005, 66: 1-12.PubMed

58.

Oliveira CC, van Veelen PA, Querido B, de Ru A, Sluijter M, Laban S, Drijfhout JW, van der Burg SH, Offringa R, van Hall T: The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. J Exp Med. 2010, 207: 207-221. 10.1084/jem.20091429.PubMedCentralPubMed

59.

Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011, 13: 822-830.PubMed

60.

Allard M, Oger R, Vignard V, Percier JM, Fregni G, Perier A, Caignard A, Charreau B, Bernardeau K, Khammari A: Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer. PLoS One. 2011, 6: e21118-10.1371/journal.pone.0021118.PubMedCentralPubMed

61.

Mouillot G, Marcou C, Zidi I, Guillard C, Sangrouber D, Carosella ED, Moreau P: Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol. 2007, 68: 277-285. 10.1016/j.humimm.2006.10.016.PubMed

62.

Lee N, Geraghty DE: HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol. 2003, 171: 5264-5271.PubMed

63.

Lee N, Ishitani A, Geraghty DE: HLA-F is a surface marker on activated lymphocytes. Eur J Immunol. 2010, 40: 2308-2318. 10.1002/eji.201040348.PubMedCentralPubMed

64.

Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ, Yan WH: HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer. Lung Cancer. 2011, 74: 504-509. 10.1016/j.lungcan.2011.04.006.PubMed

65.

Zhang X, Lin A, Zhang JG, Bao WG, Xu DP, Ruan YY, Yan WH: Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma. Int J Cancer. 2013, 132: 82-89. 10.1002/ijc.27621.PubMed

66.

Noguchi K, Isogai M, Kuwada E, Noguchi A, Goto S, Egawa K: Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res. 2004, 24: 3387-3392.PubMed

67.

Boyle LH, Gillingham AK, Munro S, Trowsdale J: Selective export of HLA-F by its cytoplasmic tail. J Immunol. 2006, 176: 6464-6472.PubMed

68.

Wainwright SD, Biro PA, Holmes CH: HLA-F is a predominantly empty, intracellular, TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol. 2000, 164: 319-328.PubMed

69.

Goodridge JP, Burian A, Lee N, Geraghty DE: HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol. 2010, 184: 6199-6208. 10.4049/jimmunol.1000078.PubMedCentralPubMed

70.

Lepin EJM, Bastin JM, Allan DSJ, Roncador G, Braud VM, Mason DY, Merwe PA, McMichael AJ, Bell JI, Powis SH, O’Callaghan CA: Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. European J Immunol. 2000, 30: 3552-3561. 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L.

71.

Sloane DE, Tedla N, Awoniyi M, MacGlashan DW, Borges L, Austen KF, Arm JP: Leukocyte immunoglobulin-like receptors: novel innate receptors for human basophil activation and inhibition. Blood. 2004, 104: 2832-2839. 10.1182/blood-2004-01-0268.PubMed

72.

Brown D, Trowsdale J, Allen R: The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 2004, 64: 215-225. 10.1111/j.0001-2815.2004.00290.x.PubMed

73.

Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier R, Pereyra F, Trocha A: A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007, 204: 2813-2824. 10.1084/jem.20061865.PubMedCentralPubMed

74.

Chapman TL, Heikeman AP, Bjorkman PJ: The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity. 1999, 11: 603-613. 10.1016/S1074-7613(00)80135-1.PubMed

75.

Willcox BE, Thomas LM, Bjorkman PJ: Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol. 2003, 4: 913-919.PubMed

76.

Shiroishi M, Kajikawa M, Kuroki K, Ose T, Kohda D, Maenaka K: Crystal structure of the human monocyte-activating receptor, “group 2” leukocyte Ig-like receptor A5 (LILRA5/LIR9/ILT11). J Biol Chem. 2006, 281: 19536-19544. 10.1074/jbc.M603076200.PubMed

77.

Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, Kato K, Kohda D, Maenaka K: Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A. 2006, 103: 16412-16417. 10.1073/pnas.0605228103.PubMedCentralPubMed

78.

Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ: Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol. 2001, 167: 5543-5547.PubMed

79.

Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, Chang C, Boyle LH, Taylor CJ, Trowsdale J, Allen RL: HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol. 2011, 186: 2990-2997. 10.4049/jimmunol.1003078.PubMed

80.

Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B: Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A. 2003, 100: 8856-8861. 10.1073/pnas.1431057100.PubMedCentralPubMed

81.

Huang J, Goedert JJ, Sundberg EJ, Cung TD, Burke PS, Martin MP, Preiss L, Lifson J, Lichterfeld M, Carrington M, Yu XG: HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med. 2009, 206: 2959-2966. 10.1084/jem.20091386.PubMedCentralPubMed

82.

Mamegano K, Kuroki K, Miyashita R, Kusaoi M, Kobayashi S, Matsuta K, Maenaka K, Colonna M, Ozaki S, Hashimoto H: Association of LILRA2 (ILT1, LIR7) splice site polymorphism with systemic lupus erythematosus and microscopic polyangiitis. Genes Immun. 2008, 9: 214-223. 10.1038/gene.2008.5.PubMed

83.

Thomas R, Matthias T, Witte T: Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2010, 38: 159-162. 10.1007/s12016-009-8148-8.PubMed

84.

Candore G, Lio D, Colonna Romano G, Caruso C: Pathogenesis of autoimmune diseases associated with 8.1 Ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev. 2002, 1: 29-35. 10.1016/S1568-9972(01)00004-0.PubMed

85.

Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF: LILRA3 Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PLoS One. 2011, 6: e19245-10.1371/journal.pone.0019245.PubMedCentralPubMed

86.

Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K: Association of human leukocyte antigen ancestral haplotype 8.1 With adverse outcome of non-Hodgkin’s lymphoma. Genes Chromosomes Cancer. 2007, 46: 500-507. 10.1002/gcc.20436.PubMed

87.

Helgadottir H, Andersson E, Villabona L, Kanter L, van der Zanden H, Haasnoot GW, Seliger B, Bergfeldt K, Hansson J, Ragnarsson-Olding B: The common scandinavian human leucocyte antigen ancestral haplotype 62.1 As prognostic factor in patients with advanced malignant melanoma. Cancer Immunol Immunother. 2009, 58: 1599-1608. 10.1007/s00262-009-0669-8.PubMed

88.

Chen Y, Gao F, Chu F, Peng H, Zong L, Liu Y, Tien P, Gao GF: Crystal structure of myeloid cell activating receptor leukocyte Ig-like receptor A2 (LILRA2/ILT1/LIR-7) domain swapped dimer: molecular basis for its non-binding to MHC complexes. J Mol Biol. 2009, 386: 841-853. 10.1016/j.jmb.2009.01.006.PubMed

89.

Lee DJ, Sieling PA, Ochoa MT, Krutzik SR, Guo B, Hernandez M, Rea TH, Cheng G, Colonna M, Modlin RL: LILRA2 Activation inhibits dendritic cell differentiation and antigen presentation to T cells. J Immunol. 2007, 179: 8128-8136.PubMedCentralPubMed

90.

Arosa FA, Santos SG, Powis SJ: Open conformers: the hidden face of MHC-I molecules. Trends Immunol. 2007, 28: 115-123. 10.1016/j.it.2007.01.002.PubMed

91.

Masuda A, Nakamura A, Maeda T, Sakamoto Y, Takai T: Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J Exp Med. 2007, 204: 907-920. 10.1084/jem.20060631.PubMedCentralPubMed

92.

Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL: HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A. 1993, 90: 12000-12004. 10.1073/pnas.90.24.12000.PubMedCentralPubMed

93.

Anfossi N, Doisne JM, Peyrat MA, Ugolini S, Bonnaud O, Bossy D, Pitard V, Merville P, Moreau JF, Delfraissy JF: Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol. 2004, 173: 7223-7229.PubMed

94.

Long EO: Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev. 2008, 224: 70-84. 10.1111/j.1600-065X.2008.00660.x.PubMedCentralPubMed

95.

Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, van der Meer A, Joosten I, Long EO: Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol. 2006, 4: e9-10.1371/journal.pbio.0040009.PubMedCentralPubMed

96.

Rajagopalan S, Long EO: KIR2DL4 (CD158d): an activation receptor for HLA-G. Front Immunol. 2012, 3: 258-PubMedCentralPubMed

97.

Miah SM, Hughes TL, Campbell KS: KIR2DL4 differentially signals downstream functions in human NK cells through distinct structural modules. J Immunol. 2008, 180: 2922-2932.PubMed

98.

Li C, Houser BL, Nicotra ML, Strominger JL: HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A. 2009, 106: 5767-5772. 10.1073/pnas.0901173106.PubMedCentralPubMed

99.

Lanier LL: NK cell recognition. Annu Rev Immunol. 2005, 23: 225-274. 10.1146/annurev.immunol.23.021704.115526.PubMed

100.

Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL: Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J. 1999, 18: 4250-4260. 10.1093/emboj/18.15.4250.PubMedCentralPubMed

101.

Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998, 391: 795-799. 10.1038/35869.PubMed

102.

Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998, 187: 813-818. 10.1084/jem.187.5.813.PubMedCentralPubMed

103.

Krawczyk M, Seguin-Estevez Q, Leimgruber E, Sperisen P, Schmid C, Bucher P, Reith W: Identification of CIITA regulated genetic module dedicated for antigen presentation. PLoS Genet. 2008, 4: e1000058-10.1371/journal.pgen.1000058.PubMedCentralPubMed

104.

Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL: Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol. 2004, 75: 486-494.PubMed

105.

Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL: Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol. 2005, 175: 5135-5145.PubMed

106.

Ohshima K, Haraoka S, Sugihara M, Suzumiya J, Kawasaki C, Kanda M, Kikuchi M: Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett. 2000, 160: 89-97. 10.1016/S0304-3835(00)00567-X.PubMed

107.

Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M: Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 2001, 61: 2759-2765.PubMed

108.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998, 396: 699-703. 10.1038/25387.PubMed

109.

Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, Caskey CT: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A. 2000, 97: 1230-1235. 10.1073/pnas.97.3.1230.PubMedCentralPubMed

110.

Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, Roth W: Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia. 2008, 10: 1049-1056.PubMedCentralPubMed

111.

Hsu TL, Chang YC, Chen SJ, Liu YJ, Chiu AW, Chio CC, Chen L, Hsieh SL: Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol. 2002, 168: 4846-4853.PubMed

112.

Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL: Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood. 2008, 111: 5054-5063. 10.1182/blood-2007-12-130609.PubMed

113.

You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL: Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood. 2008, 111: 1480-1488.PubMed

114.

Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC, Hsieh SL: Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol. 2012, 188: 2464-2471. 10.4049/jimmunol.1101101.PubMed

115.

Kamper N, Franken S, Temme S, Koch S, Bieber T, Koch N: Gamma-interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J. 2012, 26: 104-116. 10.1096/fj.11-189670.PubMed

116.

Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P: Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer. 2009, 125: 367-373. 10.1002/ijc.24401.PubMed

117.

Hessa T, Sharma A, Mariappan M, Eshleman HD, Gutierrez E, Hegde RS: Protein targeting and degradation are coupled for elimination of mislocalized proteins. Nature. 2011, 475: 394-397. 10.1038/nature10181.PubMedCentralPubMed

118.

Sasaki T, Gan EC, Wakeham A, Kornbluth S, Mak TW, Okada H: HLA-B-associated transcript 3 (Bat3)/scythe is essential for p300-mediated acetylation of p53. Genes Dev. 2007, 21: 848-861. 10.1101/gad.1534107.PubMedCentralPubMed

119.

Simhadri VR, Reiners KS, Hansen HP, Topolar D, Simhadri VL, Nohroudi K, Kufer TA, Engert A, PoggevonStrandmann E: Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One. 2008, 3: e3377-10.1371/journal.pone.0003377.PubMedCentralPubMed

120.

Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, Rothe A, Boll B, Simhadri VL, Borchmann P: Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007, 27: 965-974. 10.1016/j.immuni.2007.10.010.PubMed

121.

Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T: Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008, 40: 1407-1409. 10.1038/ng.273.PubMedCentralPubMed

122.

McIntire RH, Morales PJ, Petroff MG, Colonna M, Hunt JS: Recombinant HLA-G5 and -G6 drive U937 myelomonocytic cell production of TGF-beta1. J Leukoc Biol. 2004, 76: 1220-1228. 10.1189/jlb.0604337.PubMed

123.

Ashcroft GS: Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect. 1999, 1: 1275-1282. 10.1016/S1286-4579(99)00257-9.PubMed

124.

Zhang W, Liang S, Wu J, Horuzsko A: Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts. Transplantation. 2008, 86: 1125-1134. 10.1097/TP.0b013e318186fccd.PubMedCentralPubMed

125.

Agaugue S, Carosella ED, Rouas-Freiss N: Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood. 2011, 117: 7021-7031. 10.1182/blood-2010-07-294389.PubMed

126.

Allan DS, Colonna M, Lanier LL, Churakova TD, Abrams JS, Ellis SA, McMichael AJ, Braud VM: Tetrameric complexes of human histocompatibility leukocyte antigen (HLA)-G bind to peripheral blood myelomonocytic cells. J Exp Med. 1999, 189: 1149-1156. 10.1084/jem.189.7.1149.PubMedCentralPubMed

127.

Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O’Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A: Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol. 1998, 160: 3096-3100.PubMed

128.

Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A: Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6–STAT3 signaling pathway. Proc Natl Acad Sci U S A. 2008, 105: 8357-8362. 10.1073/pnas.0803341105.PubMedCentralPubMed

129.

Ristich V, Liang S, Zhang W, Wu J, Horuzsko A: Tolerization of dendritic cells by HLA-G. Eur J Immunol. 2005, 35: 1133-1142. 10.1002/eji.200425741.PubMed

130.

LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED: HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J. 2005, 19: 662-664.PubMed

131.

Mandelboim O, Reyburn HT, Vales-Gomez M, Pazmany L, Colonna M, Borsellino G, Strominger JL: Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med. 1996, 184: 913-922. 10.1084/jem.184.3.913.PubMed

132.

Falk CS, Steinle A, Schendel DJ: Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells. J Exp Med. 1995, 182: 1005-1018. 10.1084/jem.182.4.1005.PubMed

133.

Morel E, Bellon T: HLA class I molecules regulate IFN-gamma production induced in NK cells by target cells, viral products, or immature dendritic cells through the inhibitory receptor ILT2/CD85j. J Immunol. 2008, 181: 2368-2381.PubMed

134.

Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004, 5: 1260-1265. 10.1038/ni1138.PubMed

135.

Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H, Smyth MJ: Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 2002, 3: 83-90.PubMed

136.

Dietrich J, Cella M, Colonna M: Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol. 2001, 166: 2514-2521.PubMed

137.

HoWangYin KY, Caumartin J, Favier B, Daouya M, Yaghi L, Carosella ED, LeMaoult J: Proper regrafting of Ig-like transcript 2 after trogocytosis allows a functional cell-cell transfer of sensitivity. J Immunol. 2011, 186: 2210-2218. 10.4049/jimmunol.1000547.PubMed

138.

Le Rond S, Azema C, Krawice-Radanne I, Durrbach A, Guettier C, Carosella ED, Rouas-Freiss N: Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol. 2006, 176: 3266-3276.PubMed

139.

Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol. 2004, 172: 834-842.PubMed

140.

Huang JF, Yang Y, Sepulveda H, Shi W, Hwang I, Peterson PA, Jackson MR, Sprent J, Cai Z: TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science. 1999, 286: 952-954. 10.1126/science.286.5441.952.PubMed

141.

Cox JH, McMichael AJ, Screaton GR, Xu XN: CTLs target Th cells that acquire bystander MHC class I-peptide complex from APCs. J Immunol. 2007, 179: 830-836.PubMed

142.

Hwang I, Huang JF, Kishimoto H, Brunmark A, Peterson PA, Jackson MR, Surh CD, Cai Z, Sprent J: T cells can use either T cell receptor or CD28 receptors to absorb and internalize cell surface molecules derived from antigen-presenting cells. J Exp Med. 2000, 191: 1137-1148. 10.1084/jem.191.7.1137.PubMedCentralPubMed

143.

LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED: Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007, 109: 2040-2048. 10.1182/blood-2006-05-024547.PubMed

144.

LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED: HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A. 2004, 101: 7064-7069. 10.1073/pnas.0401922101.PubMedCentralPubMed

145.

Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F: Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003, 33: 125-134. 10.1002/immu.200390015.PubMed

146.

Puppo F, Contini P, Ghio M, Indiveri F: Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction. ScientificWorldJournal. 2002, 2: 421-423.PubMed

147.

Rajagopalan S, Long EO: A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999, 189: 1093-1100. 10.1084/jem.189.7.1093.PubMedCentralPubMed

148.

Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N: Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol. 2004, 173: 6072-6081.PubMed

Title: HLA-dependent tumour development: a role for tumour associate macrophages?
Authors: Maddalena Marchesi
Emilia Andersson
Lisa Villabona
Barbara Seliger
Andreas Lundqvist
Rolf Kiessling
Giuseppe V Masucci
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2013
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-11-247

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria

TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors

Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression

The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma

Leukemia cells induce changes in human bone marrow stromal cells

Cytokine-induced killer cells promote antitumor immunity

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage